Indegene Ltd
Incorporated in 1998, Indegene Ltd provides
solutions consisting of analytics, technology
and commercial, medical, regulatory and
safety services to life science and health
care organizations[1]
- Market Cap ₹ 13,119 Cr.
- Current Price ₹ 546
- High / Low ₹ 735 / 485
- Stock P/E 30.1
- Book Value ₹ 109
- Dividend Yield 0.37 %
- ROCE 24.8 %
- ROE 20.6 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 67.9% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 24.3%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 553 | 643 | 966 | 1,665 | 2,306 | 2,590 | 2,839 | 2,924 | |
| 511 | 499 | 736 | 1,378 | 1,910 | 2,084 | 2,292 | 2,363 | |
| Operating Profit | 42 | 144 | 230 | 287 | 396 | 505 | 548 | 561 |
| OPM % | 8% | 22% | 24% | 17% | 17% | 20% | 19% | 19% |
| 7 | -102 | -3 | -21 | 58 | 79 | 94 | 107 | |
| Interest | 6 | 9 | 7 | 6 | 31 | 49 | 22 | 14 |
| Depreciation | 17 | 19 | 26 | 33 | 60 | 76 | 80 | 82 |
| Profit before tax | 26 | 14 | 195 | 226 | 363 | 459 | 539 | 572 |
| Tax % | 45% | 191% | 23% | 28% | 27% | 27% | 25% | |
| 14 | -12 | 149 | 163 | 266 | 337 | 407 | 435 | |
| EPS in Rs | 89.98 | -40.20 | 951.96 | 937.73 | 11.99 | 15.14 | 16.95 | 18.16 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 12% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 35% |
| 3 Years: | 19% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 68% |
| 3 Years: | 29% |
| TTM: | 23% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -19% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 28% |
| 3 Years: | 24% |
| Last Year: | 21% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.31 | 0.31 | 0.31 | 0.35 | 44 | 44 | 48 |
| Reserves | 73 | -105 | 324 | 764 | 1,020 | 1,385 | 2,568 |
| 147 | 483 | 51 | 66 | 502 | 490 | 102 | |
| 108 | 222 | 220 | 524 | 638 | 627 | 609 | |
| Total Liabilities | 329 | 600 | 596 | 1,353 | 2,204 | 2,546 | 3,326 |
| 104 | 119 | 86 | 138 | 664 | 646 | 678 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Investments | 0 | 13 | 0 | 120 | 614 | 796 | 1,290 |
| 225 | 468 | 510 | 1,096 | 926 | 1,103 | 1,355 | |
| Total Assets | 329 | 600 | 596 | 1,353 | 2,204 | 2,546 | 3,326 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 65 | 22 | 172 | 297 | 130 | 508 | 442 | |
| -18 | -16 | -81 | -158 | -896 | -326 | -677 | |
| -21 | 136 | -132 | 233 | 333 | -66 | 288 | |
| Net Cash Flow | 25 | 143 | -40 | 373 | -433 | 115 | 52 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 60 | 127 | 108 | 97 | 102 | 91 | 97 |
| Inventory Days | |||||||
| Days Payable | |||||||
| Cash Conversion Cycle | 60 | 127 | 108 | 97 | 102 | 91 | 97 |
| Working Capital Days | -7 | -5 | 45 | 11 | 41 | 27 | 39 |
| ROCE % | 37% | 55% | 46% | 33% | 29% | 25% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
4h - Indegene Q2FY26 earnings call on 31 Oct 2025, 8:30 AM IST; CEO and CFO speaking.
-
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The SEBI (LODR) Regulations, 2015
4h - Board meeting on 30-Oct-2025 to approve Sep 30, 2025 quarter results and ESOP/RSU allotments.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
17 Oct - Indegene expands consulting practice, acquires WARN & Co., names Gobin Chandra Head (October 17, 2025).
-
Announcement under Regulation 30 (LODR)-Acquisition
17 Oct - Indegene subsidiary signed SPA Oct 16 2025 to acquire Warn And Co for up to GBP 3 million (100% stake).
-
Reg. 34 (1) Annual Report.
16 Oct - Annual Report FY2024-25; 27th AGM on June 26, 2025 (VC/OAVM).
Concalls
-
Oct 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT REC
-
Mar 2025TranscriptNotesPPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Aug 2024TranscriptNotesPPT
-
Jun 2024TranscriptPPTREC
Business Overview:[1]
IL is a digital-first healthcare and technology company. It helps bio pharmaceutical, emerging biotech and medical device companies to develop products and get them to market. Company brings together healthcare domain expertise, technology and an agile operating model to provide diverse solutions for patients and physicians.